Document Detail

Management of type 2 diabetes mellitus: is it time for a paradigm shift?
MedLine Citation:
PMID:  18370694     Owner:  NLM     Status:  In-Data-Review    
Type 2 diabetes mellitus is a multi-organ disease that results from the combination of insulin resistance and a beta-cell secretory defect. The worldwide prevalence of type 2 diabetes has increased substantially during the past decade, and patients with this disease continue to experience a high incidence of morbidity and mortality. Because the complications associated with this disease affect multiple organ systems and have a dramatic impact on daily life, the importance of lowering glycosylated hemoglobin (HbA(1c)) levels to within the normal range cannot be overemphasized. The introduction in the past decade of several new classes of pharmacological agents to treat patients with type 2 diabetes now provides the opportunity to focus therapy on treating the underlying disease process instead of just reacting to the blood glucose levels. The thiazolidinediones are unique in their ability to modulate free fatty acid metabolism and to improve insulin sensitivity. These agents also exert numerous nonglycemic effects on the vasculature and lipid metabolism and may improve many of the risk factors associated with metabolic syndrome. Data from the United Kingdom Prospective Diabetes Study (UKPDS) group showed that conventional methods of managing type 2 diabetes, including the use of sulfonylureas or biguanides, do not provide long-term glycemic control. Consequently, new treatment paradigms stressing the earlier use of thiazolidinediones, either alone or in combination with metformin, may lead to more durable glycemic control, thus facilitating the reduction of complications in patients with type 2 diabetes.
Kathleen L Wyne
Related Documents :
11921434 - Differentiating members of the thiazolidinedione class: a focus on efficacy.
11985534 - Effects of combined pioglitazone and metformin on diabetes and obesity in wistar fatty ...
15855334 - Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptak...
20435794 - Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mil...
11836304 - Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a p...
17394534 - Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabete...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Metabolic syndrome and related disorders     Volume:  2     ISSN:  1557-8518     ISO Abbreviation:  Metab Syndr Relat Disord     Publication Date:  2004  
Date Detail:
Created Date:  2008-03-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101150318     Medline TA:  Metab Syndr Relat Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  251-62     Citation Subset:  -    
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insulin Resistance and Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy.
Next Document:  Immunosuppression and metabolic syndrome in renal transplant recipients.